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Patients with celiac disease (CD), characterized histologically by villous atrophy (VA) of the
small intestine, have an increased risk of ischemic heart disease (IHD) and atrial fibrillation
(AF), risks that persist for years after commencing the gluten-free diet. It is unknown wheth-
er persistent VA on follow-up biopsy, rather than mucosal healing, affects the risk of IHD
or AF.
Methods
We identified patients with histologic evidence of CD diagnosed at all 28 pathology depart-
ments in Sweden. Among patients who underwent a follow-up small intestinal biopsy, we
compared patients with persistent VA to those who showed histologic improvement, with re-
gard to the development of IHD (angina pectoris or myocardial infarction) or AF.
Results
Among patients with CD and a follow-up biopsy (n = 7,440), the median age at follow-up bi-
opsy was 25 years, with 1,063 (14%) patients who were60 years at the time of follow-up
biopsy. Some 196 patients developed IHD and 205 patients developed AF. After adjusting
for age, gender, duration of CD, calendar period, and educational attainment, there was no
significant effect of persistent VA on IHD (adjusted HR 0.97; 95%CI 0.73–1.30). Adjusting
for diabetes had a negligible effect (adjusted HR 0.98; 95%CI 0.73–1.31). There was no
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significant association between persistent VA and the risk of AF (adjusted HR 0.98; 95%CI
0.74–1.30).
Conclusions
In this population-based study of patients with CD, persistent VA on follow-up biopsy was
not associated with an increased risk of IHD or AF. Failed mucosal healing does not influ-
ence the risk of these cardiac events.
Introduction
Celiac disease (CD) is an immune-based disorder characterized by small intestinal inflamma-
tion and villous atrophy (VA) that is triggered by the ingestion of gluten in genetically-
susceptible individuals.[1] Now present in approximately 1% of the population of the United
States, patients with CD may present with a myriad of symptoms.[2,3] Patients may exhibit di-
arrhea and malabsorption, but extra-intestinal manifestations are manifold and can include fa-
tigue, metabolic bone disease, neuropsychiatric symptoms, and reproductive disorders.[1]
Patients with CD have an increased risk of death due to cardiovascular causes, a risk that per-
sists (though is attenuated) in the years following the diagnosis of CD and the commencement
of a gluten-free diet.[4] Cardiovascular diseases that have been found to be associated with CD
include atrial fibrillation (AF), [5] cerebrovascular events, [6] cardiomyopathy, [7] and ische-
mic heart disease (IHD).[8] Given that the IHD is the leading cause of death in the world, [9]
and that AF is a significant contributor to cerebrovascular disease, [10] the increased risks of
IHD and AF are important drivers of overall mortality risk among patients with CD.[4]
Patients with CD who develop IHD have a risk-factor profile that is distinct from patients
without CD who develop IHD. [11] The risk of IHD in patients with CD may be conferred by a
chronic inflammatory state.[11,12] This distinct risk is invoked because CD patients with IHD
have a lower mean body mass index, lower total cholesterol, and lower rates of smoking than
their non-CD counterparts with IHD. While similar risk factor analyses have not been per-
formed in patients with CD who develop AF, the latter condition is associated with elevated in-
flammatory markers as well.[13]
Follow-up biopsy has emerged as a potentially important approach to risk-stratify CD pa-
tients with regard to long-term prognosis. Rates of persistent VA are variable in the literature
(occurring in at least 30% of patients in most series), [14–19] but persistent VA is inversely cor-
related with adherence to the gluten-free diet.[16,18,19] While persistent VA does not impact
overall mortality or mortality due to cardiovascular disease, [20] there have been no studies in-
vestigating a link between persistent VA and the incidence of IHD and AF, two cardiac condi-
tions associated with CD. Persistent VA may be a marker of disease severity and ongoing
inflammation, which may in turn impact the risk of cardiovascular disease. The finding of per-
sistent VA is clinically relevant, as it can reflect gluten exposure and may motivate patients to
improve dietary adherence.[14] Persistent VA has been shown to be associated with an in-
creased risk of lymphoproliferative malignancy[21] and hip fracture, [22] two outcomes that
are more common in patients with CD than among the general population. It is unknown
whether findings from follow-up histology predict the incidence of IHD or AF in
these patients.
We therefore aimed to determine whether the results of follow-up biopsy among patients
with CD influence the risk of developing IHD or AF.
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Methods
Identification of patients with CD
During the years 2006–2008 we queried all (n = 28) pathology departments in Sweden for re-
ports of VA, as identified by SnoMed codes. Details regarding this population-based database
have been published previously.[4,23] In brief, VA was identified by Swedish pathologists and
a prior validation study demonstrated that, among patients identified via these histology codes,
a clinical diagnosis of CD was present in 95% of patients; alternative/comorbid diagnoses were
rare (with inflammatory bowel disease, the most common comorbidity, present in 0.3% of
1,534 manually reviewed patient records).[23]
The patients in this analysis are those with CD who underwent more than one duodenal bi-
opsy; they therefore represent a subset of all CD patients, who were included in our earlier
studies that found an increased risk of IHD and AF in CD.[5,8] We identified those CD pa-
tients who underwent follow-up biopsy between 6 months and 5 years after initial CD diagno-
sis. Those patients who had a modified Marsh histopathology score[24,25] of 3 were classified
as having persistent VA, while those with a less severe score were classified as healed.
Identification of cases of IHD
Data on IHD were obtained from the Swedish Patient Registry containing both inpatient data
(since 1964, and nationwide since 1987) and hospital-based outpatient data (since 2001); data
for fatal MI were obtained from the Swedish Cause of Death Registry.[26] The composite out-
come of IHD consisted of either inpatient visits associated with myocardial infarction (MI) or
angina pectoris, or death from MI. We used the same international classification of disease
(ICD) codes as in our previous paper on IHD (ICD 10: I20–22 and corresponding ICD7–9
codes).[8]
Statistical considerations
We used Cox proportional hazard models to compare the risk of risk of IHD among those with
persistent VA versus those with mucosal healing on follow-up biopsy; we report risk estimates
as hazard ratios (HR) and corresponding 95% confidence intervals (CI). Follow-up time began
on the day of the follow-up biopsy and ended on the date of death, emigration, or development
of IHD, or December 31, 2009, whichever occurred first. In this analysis we chose a priori the
following covariates in the model: age at follow-up biopsy, gender, duration of CD at the time
of follow-up biopsy, calendar period of follow-up biopsy, and educational attainment. In the
case of children, the highest educational attainment of either parent was substituted. Because
the risk of sequelae in CD (including mortality due to cardiovascular causes) changes over
time, [4] we repeated this analysis, recalculating the association between persistent villous atro-
phy and the development of IHD during the following 3 pre-specified time strata:<1 year, 1–5
years, and>5 years after the patient’s follow-up biopsy. We then performed stratified analysis
by age, gender, and calendar period of follow-up biopsy. In a post-hoc power analysis using an
alpha of 0.05, we had 80% power to detect an association between persistent VA and IHD at a
relative risk of 1.48.
Sensitivity Analyses
We performed several additional analyses to test the robustness of our results. We repeated the
primary analysis, now treating age as a continuous (rather than a categorical) covariate, and
then using age as the time scale. So as to determine whether duration of VA was influencing
the main association, we repeated the analysis, removing duration of CD from the multivariate
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model. Although diabetes mellitus has not been tested with regard to a potential impact on mu-
cosal healing, because of its strong association with IHD we repeated the primary analysis, now
including the presence of diabetes mellitus (type 1 or 2) as a covariate.
Persistent VA may be a consequence of longstanding untreated CD, i.e. prolonged gluten
exposure prior to the biopsy diagnosis of CD. It is unknown whether such longstanding un-
treated CD could impact the development of IHD prior to CD diagnosis. For this reason, we
subsequently sought to determine whether a prior diagnosis of IHD was associated with persis-
tent VA among patients who were subsequently diagnosed with CD and then underwent
follow-up biopsy. In this subsequent analysis, we assessed for this association using multiple lo-
gistic regression, adjusting for the same covariates as those used in our Cox model for the
primary analysis.
Atrial fibrillation
CD has been previously shown to increase the risk of subsequent development of AF.[5] So as
to determine whether the development of AF influenced the results of our primary analysis, we
tested for an association between persistent VA and the subsequent development of AF. For
this analysis, we used the following diagnosis codes to identify inpatients and outpatients with
AF: ICD7: 433.12; ICD8: 427.92; ICD9: 427D; ICD10: I48. We excluded all patients with a diag-
nosis of AF preceding the date of follow-up biopsy, and our adjusted risk estimates used the
same covariates as those used for the primary analysis.
We used SAS version 9.3 (Cary, NC) for all statistical analyses. All reported p values are
two-sided. This study was approved by the Research Ethics Committee of the Karolinska Insti-
tute on June 14th, 2006.
Results
Characteristics of patients who underwent follow-up biopsy
We identified 9,725 patients with CD who underwent a follow-up biopsy. Of these, 2,077 un-
derwent a follow-up biopsy outside of the time frame of 6 months to 5 years after initial CD di-
agnosis. An additional 208 patients were excluded due to the development of IHD prior to
their follow-up biopsy. The remaining 7,440 patients with CD who underwent follow-up biop-
sy were included for further analysis.
As has been reported previously, [20] those patients who underwent follow-up biopsy were
slightly younger than those who did not (mean age at CD diagnosis 28.4 versus 33.4 years,
p<0.0001). In our prior study examining the overall risk of IHD patients with CD, we matched
each CD patient with up to 5 controls via Sweden’s Total Population Register, using the follow-
ing matching parameters: age, gender, county, and calendar year.[8] In this subset of patients
with CD who underwent follow-up biopsy, the overall risk of developing IHD as compared to
these previously matched controls and stratified by age, gender, and year, is shown in S1 Table.
The overall risk of IHD in these patients with CD compared to controls did not reach statistical
significance (HR 1.09; 95%CI 0.95–1.25). This point estimate is lower than (though its confi-
dence interval includes) the risk estimate previously reported for all patients with CD, regard-
less of whether a follow-up biopsy was performed (HR 1.19).[8]
Among those who had a follow-up biopsy during the pre-specified time period, 64% were
female (Table 1). Some 45% of these patients had their follow-up biopsy performed between
one and two years after their initial CD diagnosis. In the majority of patients (52%) follow-up
biopsy was performed after the year 2000. Among those who had a follow-up biopsy, 43% ex-
hibited persistent VA. We have previously reported that factors associated with persistent VA
include older age, male gender, and low educational attainment.[27]
Mucosal Healing and Heart Disease
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Risk of IHD
The median observation time after CD diagnosis was 10.6 years (IQR 7.1–16.0 years) and the
median observation time after follow-up biopsy was 8.9 years (IQR 5.5–14.1 years). During
this period, 196 patients (2.6%) developed IHD. Among patients with CD who had a follow-up
biopsy, the overall incidence of IHD was 257 per 100,000 person-years. This rate was greater
among those with persistent VA (298 per 100,000 person-years) as compared to those with
mucosal healing (214 per 100,000 person-years), yielding a trend towards a positive unadjusted
association (HR 1.30; 95%CI 0.97–1.73, p = 0.08).
Table 1. Characteristics of the patient cohort with CD and follow-up biopsies.
Characteristic Number (%)










Interval between diagnosis and follow-up biopsy
6 months–1 year 1,950 (26)
Between 1 and 2 years 3,352 (45)
2–5 years 2,138 (29)





Mucosal healing 4,242 (57)
Persistent villous atrophy 3,198 (43)
Developed IHD during follow-up:* 196 (2.6))
Angina pectoris 111 (1.5)
Unstable angina pectoris 30 (0.4)
MI 176 (2.4)
Fatal MI 37 (0.5
Developed AF during follow-up:† 205 (2.7)
(Excludes patients with a diagnosis of IHD prior to follow-up biopsy, n = 208).
CD, celiac disease
IHD. Ischemic heart disease
MI, Myocardial infarction
*The sum of IHD subtypes is greater than the total number of patients with IHD because of patients who
had more than one type of IHD event
†Among patients without a history of AF at the time of follow-up biopsy (n = 7,530).
doi:10.1371/journal.pone.0117529.t001
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After adjusting for age at follow-up biopsy, gender, calendar period of follow-up biopsy, de-
gree of educational attainment, and duration of CD, there was no significant difference in risk
of IHD between those with mucosal healing and those with VA (HR 0.97; 95%CI 0.73–1.30,
p = 0.85). The primary confounding influence was age; adjusting for age alone resulted in the
HR moving from 1.30 down to 1.07. In this model, factors associated with an increased risk of
IHD included male sex (HR 2.08; 95%CI 1.56–2.78, p<0.0001), increased age (HR per year
1.09; 95%CI 1.08–1.10, p<0.0001), and lower degree of educational attainment (HR for col-
lege/university versus<2 years of high school 0.54; 95%CI 0.33–0.87, p = 0.01).
When stratifying risk of IHD over time after follow up biopsy (Table 2), in none of the pre-
specified time strata did this association meet statistical significance. A test to determine
whether the association between persistent VA and the development of IHD differs over time
showed no significant interaction between persistent VA and time after follow-up biopsy with
regard to the risk of IHD (p = 0.20).
There was no observed association between persistent VA and the development of IHD
when stratifying by gender, age, and calendar year after follow-up biopsy (Table 3). When re-
stricting the population to adults (age20 years), the incidence of IHD was 534 per 100,000
person years of observation, and there was no association between persistent VA and risk of
IHD (HR 0.97; 95%CI 0.73–1.30, p = 0.85) Neither was there a significant association between
persistent VA and IHD subtypes, including angina pectoris, unstable angina pectoris, myocar-
dial infarction, and fatal myocardial infarction (Table 4). The association between persistent
VA and IHD remained non-significant when repeating the analysis, now with age treated as a
continuous covariate (HR 0.95; 95%CI 0.71–1.27, p = 0.72), when age was used as the time
scale (HR 0.95; 95%CI 0.71–1.27, p = 0.12) and when excluding the duration of CD from the
model (HR 0.98; 95%CI 0.74–1.31, p = 0.90). The relationship similarly was null when includ-
ing the presence of diabetes mellitus in the multivariate model (HR 0.98; 95%CI 0.73–1.31, p =
0.88). The positive association between diabetes and IHD in this population did not meet sta-
tistical significance (HR 1.79; 95%CI 0.91–3.52, p = 0.09).
Table 2. Association of persistent villous atrophy with IHD overall, and stratified by time after follow-up biopsy.
Stratum Number of events Incidence per 100,000 PY Adjusted† HR (95% CI) p value
Overall 257
Mucosal healing 80 214 1.0
Persistent villous atrophy 116 298 0.97 (0.73–1.30) 0.85
<1 year 189
Mucosal healing 3 71 1.0
Persistent villous atrophy 11 346 2.97 (0.83–10.7) 0.09
1–5 years 186
Mucosal healing 24 156 1.0
Persistent villous atrophy 27 224 0.90 (0.52–1.56) 0.69
>5 years 316
Mucosal healing 53 299 1.0
Persistent villous atrophy 78 329 0.90 (0.63–1.29) 0.57
HR, Hazard Ratio
†Adjusted for patient age at follow-up biopsy, gender, calendar period of follow-up biopsy, education, and duration of celiac disease at the time of follow-
up biopsy
doi:10.1371/journal.pone.0117529.t002
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Persistent VA and prior IHD
Of 7,648 CD patients who underwent follow-up biopsy between 6 months and 5 years after ini-
tial CD diagnosis, 208 patients developed IHD prior to their follow-up biopsy. Although this
was more common among those who developed persistent VA (3.6%) as compared to those
with mucosal healing (2.1%), after adjusting for age, gender, calendar period of follow-up biop-
sy and educational attainment, there was no significant association between prior IHD and
subsequent persistent VA (OR 1.07; 95%CI 0.79–1.46, p = 0.66).
Table 3. Association of persistent villous atrophy with IHD, stratified by gender, age, and year of CD diagnosis.
Stratum Number of events Incidence per 100,000 PY Adjusted† HR (95% CI) p value
Gender
Male 380
Mucosal healing 41 307 1.0
Persistent villous atrophy 63 450 0.94 (0.63–1.41) 0.76
Female 188
Mucosal healing 39 163 1.0
Persistent villous atrophy 53 213 1.07 (0.71–1.64) 0.74
Age at follow-up biopsy (years)
<20 0
Mucosal healing 0 0 1.0
Persistent villous atrophy 0 0 — —
20–39 71
Mucosal healing 3 41 1.0
Persistent villous atrophy 6 112 1.73 (0.42–7.14) 0.45
40–59 433
Mucosal healing 28 384 1.0
Persistent villous atrophy 43 472 1.03 (0.63–1.68) 0.91
60 1509
Mucosal healing 49 1464 1.0
Persistent villous atrophy 67 1545 0.94 (0.64–1.36) 0.72
Calendar Year of Follow-up Biopsy
1989 and before 319
Mucosal healing 19 418 1.0
Persistent villous atrophy 29 277 0.71 (0.39–1.29) 0.26
1990–1999 261
Mucosal healing 36 213 1.0
Persistent villous atrophy 64 299 1.15 (0.76–1.74) 0.50
2000 and after 210
Mucosal healing 25 157 1.0
Persistent villous atrophy 23 328 0.91 (0.51–1.61) 0.74
HR, Hazard ratio
IHD. Ischemic heart disease
†Adjusted for patient age at follow-up biopsy, gender, calendar period of follow-up biopsy, education, and duration of celiac disease at the time of follow-
up biopsy.
doi:10.1371/journal.pone.0117529.t003
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Risk of AF
Of 7,648 CD patients who underwent follow-up biopsy between 6 months and 5 years after
their initial CD diagnosis, 118 patients developed AF prior to their follow-up biopsy. Of the re-
maining 7,530 patients, the incidence of AF was 266 per 100,000 person-years. Among those
with persistent VA, the incidence of AF was 305 per 100,000 person-years, while among those
with mucosal healing the incidence of AF was 226 per 100,000 person years. This yielded a
positive unadjusted association between persistent VA and AF (HR 1.31; 95%CI 0.99–1.73,
p = 0.06).
After adjusting for the above covariates, there was no significant difference in the risk of AF
between those with mucosal healing and those with persistent VA (HR 0.98; 95%CI 0.74–1.30,
p = 0.88). As was the case in IHD, the primary confounder was age; addition of age alone into
the model led to a diminution of the HR from 1.31 to 1.03. The association between persistent
VA and AF remained null when the analysis was repeated, using age as the time scale (HR
0.94; (95%CI 0.71–1.26, p = 0.69). Factors associated with an increased risk of AF included
male sex (HR 1.98; 95%CI 1.49–2.62, p<0.0001), and increased age (HR per year 1.10;95%
1.09–1.11, p<0.0001). As was the case for IHD, adding diabetes to the multivariate model did
not change the null association between persistent VA and AF (HR 0.98; 95%CI 0.74–1.30,
p = 0.89). The association between diabetes and AF did not meet statistical significance (HR
1.43; 95%CI 0.75–2.71, p = 0.28). Quantifications of the association between persistent VA and
AF stratified by gender, age, and calendar period are shown in Table 5. When restricting the
population to adults (age20 years), the incidence of AF was 543 per 100,000 person years of
Table 4. Risk of IHD type (myocardial infarction, stable angina, and unstable angina), and risk of
death due to IHD in patients with CD who have persistent villous atrophy on follow-up biopsy,
compared to those with mucosal healing.
Number of events Adjusted† HR (95% CI) p value
IHD Overall
Mucosal recovery 80 1.0
Persistent villous atrophy 116 0.97 (0.73–1.30) 0.85
Angina pectoris
Mucosal recovery 47 1.0
Persistent villous atrophy 64 0.94 (0.64–1.38) 0.74
Unstable angina pectoris
Mucosal recovery 14 1.0
Persistent villous atrophy 16 0.71 (0.34–1.48) 0.36
Myocardial Infarction
Mucosal recovery 70 1.0
Persistent villous atrophy 106 1.03 (0.76–1.40) 0.85
Fatal MI
Mucosal recovery 16 1.0
Persistent villous atrophy 21 0.74 (0.38–1.43) 0.37
CD, celiac disease
HR, Hazard ratio
IHD. Ischemic heart disease
MI, Myocardial infarction
†Adjusted for patient age at follow-up biopsy, gender, calendar period of follow-up biopsy, education, and
duration of celiac disease at the time of follow-up biopsy
doi:10.1371/journal.pone.0117529.t004
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observation, and there was no association between persistent VA and risk of AF (HR 0.96; 95%
CI 0.72–1.28, p = 0.78).
Discussion
In this analysis of a population-based database of patients with CD who underwent a follow-up
biopsy, we found that there was no independent increased risk of developing IHD or AF
among patients with persistent VA compared to those with mucosal healing. This null finding
was present in both genders, across age strata, and persisted over time after follow-up biopsy.
Table 5. Risk of atrial fibrillation in patients with CD according to follow-up histology.
Stratum Number of events Incidence per 100,000 PY Adjusted† HR (95% CI) p value
Overall 266
Mucosal healing 85 226 1.0
Persistent villous atrophy 120 305 0.98 (0.74–1.30) 0.88
Gender
Male 389
Mucosal healing 42 312 1.0
Persistent villous atrophy 66 462 1.00 (0.67–1.48) 0.98
Female 197
Mucosal healing 43 179 1.0
Persistent villous atrophy 54 215 1.01 (0.67–1.52) 0.96
Age at follow-up biopsy (years)
<20 5
Mucosal healing 0 0
Persistent villous atrophy 2 10 NC NC
20–39 63
Mucosal healing 6 82 1.0
Persistent villous atrophy 2 37 0.34 (0.07–1.80) 0.21
40–59 341
Mucosal healing 21 282 1.0
Persistent villous atrophy 36 389 1.21 (0.69–2.12) 0.50
60 1718
Mucosal healing 58 1695 1.0
Persistent villous atrophy 80 1735 0.94 (0.67–1.32) 0.72
Calendar Year of Follow-up Biopsy
1989 and before 198
Mucosal healing 14 305 1.0
Persistent villous atrophy 16 151 0.61 (0.29–1.26) 0.18
1990–1999 270
Mucosal healing 42 247 1.0
Persistent villous atrophy 62 287 0.87 (0.59–1.30) 0.51
2000 and after 306
Mucosal healing 29 181 1.0
Persistent villous atrophy 42 582 1.38 (0.85–2.23) 0.19
CD, celiac disease; HR, Hazard ratio; NC Not calculated.
†Adjusted for patient age at follow-up biopsy, gender, calendar period of follow-up biopsy, education, and duration of celiac disease at the time of follow-
up biopsy
doi:10.1371/journal.pone.0117529.t005
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These negative findings suggest that follow-up histology does not risk-stratify patients for the
development of IHD or AF, with the caveat that a small positive association cannot be ruled
out in certain subgroups due to limited statistical power.
We had hypothesized that mucosal healing would be associated with a decreased risk of sub-
sequent IHD and AF. This hypothesis was based on the observation that patients with CD de-
velop IHD and AF at a greater rate than would be expected in the general population[8]
despite the observation that traditional IHD risk factors such as smoking and hyperlipidemia
are less common in patients with CD.[28–30] It seemed plausible that the chronic inflammato-
ry state inherent to CD was responsible for this increased, and that chronic inflammation re-
flected in follow-up histology could be of importance to assess cardiovascular risk in these
patients. There is precedent for such a phenomenon, as patients with rheumatoid arthritis have
an increased risk of cardiovascular events and this risk has been attributed to a chronic inflam-
matory state.[31] Moreover, chronic inflammation as reflected by the erythrocyte sedimenta-
tion rate appears to correlate with the severity of VA in patients with CD.[32] Our hypothesis
was bolstered by the observation that the risk of IHD has previously been shown to be highest
in the first year after diagnosis of CD (HR 1.77) with a diminished (but still significantly in-
creased) risk beyond 5 years (HR 1.23), [8] suggesting that for a proportion of patients with
CD who strictly adhere to the gluten-free diet, the histologic activity normalizes, and immune
activation decreases along with cardiovascular risk.
Our null findings with regard to follow-up histology stand in contrast to this theoretical
model. One potential explanation for these null findings is that VA is not an adequate marker
for immune activation in patients with CD. Indeed, the previous study examining IHD risk in
CD found that elevated risk of IHD in patients with CD (HR 1.19) was similar in magnitude to
those with normal histology but elevated CD antibodies (HR 1.14), a phenomenon potentially
representing future CD.[4] If such patients without VA are at increased risk of IHD, then heal-
ing of VA in CDmay not be expected to impact IHD risk. Another possibility is that patients
with persistent VA on a first follow-up biopsy may not reflect long-term mucosal healing rates;
indeed, in one study of patients undergoing serial small intestinal biopsy at a referral center,
the prevalence of mucosal healing was greater at 5 years (66%) than at 3 years (34%), suggest-
ing that some patients gradually heal over subsequent years.[18] In this population-based data-
base, the prevalence of persistent VA was similar among those whose follow-up biopsy was
performed 1–2 years after diagnosis and 2–5 years after diagnosis, [27] suggesting that gradual
mucosal healing is not a widespread phenomenon, at least within this time-frame. Another po-
tential explanation for our null findings is that patients who underwent follow-up biopsy may
represent a healthier subset of patients with CD than those who did not. Indeed, a follow-up bi-
opsy may be deferred due to medical comorbidities which may in turn impact the risk of IHD.
Supporting this notion is our finding, previously reported, that the overall mortality risk of pa-
tients who underwent follow-up biopsy was slightly lower than those CD patients who did not
undergo follow-up biopsy.[20] Our null findings suggest that, although there is evidence that
the risk of IHD along with intermediate biomarkers diminishes over time, [12] mucosal healing
is not a marker for reduced cardiovascular risk. In our analysis of AF, another cardiac condi-
tion that is associated with CD, we likewise found that persistent VA is not an independent
predictor of this outcome.
Although our adjusted risk estimate showed no significant association between persistent
VA and the subsequent development of IHD, the unadjusted incidence of IHD was greater
among those with persistent VA (298 per 100,000 person-years) compared to those with muco-
sal healing (214 per 100,000 person-years). An unadjusted Cox model found a greater risk of
IHD among those with persistent VA that nearly met statistical significance (HR 1.30; 95% CI
0.97–1.73, p = 0.08). This contrast between unadjusted and adjusted risk estimates is driven
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primarily by the confounding influence of age. Increased age itself is associated with persistent
VA, and this may be an intrinsic effect of aging, rather than a reflection of dietary adherence.
[27] Increased age is associated with an increased risk of persistent VA, [27,33,34] and is a
strong predictor of IHD.[35] Indeed, we found that when adjusting only for age, the risks of
IHD and AF moved decisively towards the null. Therefore, although patients with persistent
VA are more likely to develop IHD, this is primarily because they are older than those with
mucosal healing. This phenomenon was also present in our analysis of AF, as age is associated
with this outcome as well as with persistent VA.
This is the first study to our knowledge investigating the risk of IHD and AF according to
follow-up histology in CD. Strengths of this study include its large sample size; despite the fact
that the majority of patients in this database were children, the large sample size allowed us to
test for this association in 1,063 patients older than 60 years, an age group in which IHD and
AF are common.[36] We were also able to examine whether certain IHD subtypes (angina pec-
toris versus myocardial infarction) were more common in patients with persistent VA. Limita-
tions of this study include the fact that data on only one follow-up biopsy were available,
leaving open the possibility that a one-time biopsy result may not affect IHD risk but long term
mucosal healing may still exert an effect. The low number of events in the younger age strata
limited our ability to generate precise risk estimates for these groups, given the rarity of IHD
and AF in individuals younger than 40. This also impacted the overall power of this study, and
it remains possible that persistent VA exerts an influence on the outcomes of IHD and AF that
our study was insufficiently powered to detect. As the increased risk of IHD in CD is modest in
magnitude (with a previous study finding a HR of 1.19), [8] perhaps the association between
follow-up histology and cardiovascular outcomes is similarly modest in magnitude. Indeed,
this was the case in our prior study regarding lymphoproliferative malignancy, in which the
overall risk of that outcome compared to the general population (HR 2.82) was greater than
the risk-stratifying effect of persistent VA compared to CD patients who exhibited mucosal
healing (HR 2.26).[21]
The reliance on claims codes for the diagnosis of CD leaves open the possibility of misclassi-
fication, but this concern is largely mitigated by a previous validation study demonstrating a
high positive predictive value for the use of the claims codes employed in the development of
this database.[23] Hospital-based diagnoses of MI and AF in particular have been shown to
have high accuracy in Sweden, [37–39] although it should be admitted that IHD diagnoses
were not adjudicated specifically for the purpose of this study. We lacked data regarding circu-
lating markers of inflammation, such as C-reactive protein (CRP), which correlates with IHD
risk.[40] Of note, a previous analysis of this database found that CRP levels among CD patients
with IHD were similar to CRP levels to non-CD patients with IHD.[11]
We acknowledge that this study is limited by a lack of data regarding several important risk
factors for IHD and for AF. Hypocholesterolemia is a feature of CD, [30] and increases in cho-
lesterol levels, particularly high density lipoproteins, have been observed after commencement
of the gluten-free diet.[41] In this population-based database of patients with CD who under-
went follow-up biopsy, our ability to determine risk factors for both of these conditions was
limited to ascertainment of age, gender, and diabetes. We therefore could not adjust for risk
factors for IHD and/or AF, such as hypertension, dyslipidemia, smoking, alcohol use, and hy-
perthyroidism. It has been shown that traditional cardiovascular risk factors (such as smoking
and hypertension) are less likely to be present in individuals with CD who had an ischemic car-
diac event, as compared to non-CD patients who had an ischemic cardiac event.[11] While the
risk for AF has been shown to be increased in patients with CD, a similar analysis of compara-
tive risk factors has not been performed to date. Because we lacked data on these traditional
risk factors, if they correlated positively with the outcomes of IHD and AF, and negatively with
Mucosal Healing and Heart Disease
PLOS ONE | DOI:10.1371/journal.pone.0117529 January 30, 2015 11 / 14
the exposure of persistent VA, negative confounding remains a possibility; adjustment for
these variables may move our risk estimates away from the null. Patients with CD tend to have
more favorable lipid profiles and may have lower rates of smoking than the general population,
[30] though data on smoking are conflicting.[42] Of note, we found that diabetes exerted a
modest risk on our outcomes, which did not meet statistical significance, and that adjusting for
diabetes in our analysis did not affect the null association between persistent VA and these out-
comes. Therefore, although the lack of information regarding smoking, dyslipidemia, and hy-
pertension is a limitation of our study, it is unlikely that this limitation is unduly influencing
our finding of a null association between persistent VA and the outcomes of IHD and AF.
In conclusion, this analysis of more than 7,000 patients with CD undergoing follow-up bi-
opsy found no significant association between persistent VA and the subsequent development
of IHD or AF. Although patients with persistent VA had higher rates of IHD and AF, this rela-
tionship was due to the confounding influence of age. As there was no protective effect of mu-
cosal healing in decreasing the risk of IHD, our results suggest that clinical management of CD
does not necessarily alter cardiovascular risk, and that other factors such as genetic influences
may explain the relationship between CD and cardiovascular disease. Our results also suggest
that even patients with mucosal healing require surveillance for IHD, coronary risk factor mod-
ification, and preventive measures such as aspirin in select patients. Future studies should in-
vestigate novel biomarkers of inflammation in CD that may impact the risk of IHD and AF.
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